Diabetes pill may halt deadly liver scarring in hepatitis b
NCT ID NCT05147090
Summary
This study is testing whether empagliflozin, a medication for diabetes, can prevent or slow the progression of liver scarring (fibrosis and cirrhosis) in people with chronic hepatitis B. The 106 participants are already taking standard antiviral drugs but still have significant liver scarring. They will take either empagliflozin or a placebo pill daily for three years to see if the drug helps keep their liver from getting stiffer and more damaged.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CIRRHOSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The University of Hong Kong/Queen Mary Hospital
Hong Kong, Hong Kong, China, 852, Hong Kong
Conditions
Explore the condition pages connected to this study.